| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0011 | 9530018H14Rik | breast cancer | qPCR, Luciferase reporter assay etc. | breast cancer tissue, cell lines(NMuMG, 4T1) | up-regulated | expression | The level of expression of lncRNA-HIT in normal breast tissue was low and gradually increased to invasive carcinoma suggesting lncRNA-HIT may play a role in tumor progression in humans. These data further support the findings demonstrating the involvement of lncRNA-HIT in EMT and invasion as observed in NMuMG and 4T1 cells, and suggest that conserved human lncRNA-HIT could play a pivotal role in breast cancer metastasis. | 25605728 | Lnc2Cancer |
| EL0235 | BCAR4 | breast cancer | microarray, qPCR, knockdown etc. | cell lines (ZR-75-1, MCF7, BCAR4 etc.) | differential expression | expression | BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. | 22892392 | LncRNADisease Lnc2Cancer |
| EL0235 | BCAR4 | breast cancer | N/A | N/A | N/A | N/A | BCAR4 binding of SNIP1 and PNUTS in response to CCL21 releases the SNIP1's inhibition of p300-dependent histone acetylation, which in turn enables the BCAR4-recruited PNUTS to bind H3K18ac and relieve inhibition of RNA Pol II via activation of the PP1 phosphatase. | 25416949 | LncRNADisease |
| EL0235 | BCAR4 | breast cancer | qPCR etc. | cell line (ZR-75-1) | up-regulated | N/A | Breast cancer anti-estrogen resistance 4 (BCAR4), caused OH-TAM resistance and anchorage-independent cell growth in ZR-75-1 cells. | 16778085 | LncRNADisease Lnc2Cancer |
| EL0235 | BCAR4 | breast cancer | qPCR etc. | cell line (ZR-75-1) | up-regulated | expression | BCAR4 is expressed in 27% of primary breast tumors. Forced expression of BCAR4 in human ZR-75-1 and MCF7 breast cancer cells resulted in cell proliferation in the absence of estrogen and in the presence of various antiestrogens.BCAR4 may be a good target for treating antiestrogen-resistant breast cancer. | 21506106 | LncRNADisease Lnc2Cancer |
| EL0235 | BCAR4 | breast cancer | qPCR, Western blot etc. | cell lines (ZR-75-1, BCAR3, EGFR etc.) | up-regulated | expression | High BCAR4 mRNA levels were associated with poor MFS and overall survival, reflecting tumour aggressiveness. | 20859285 | LncRNADisease Lnc2Cancer |
| EL0237 | BCYRN1 | breast cancer | ISH, Northern hybridization etc. | breast cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
| EL0237 | BCYRN1 | breast cancer | microarray, ISH etc. | breast cancer tissue | up-regulated | expression | In ductal carcinomas in situ, furthermore, significant BC200 (BCYRN1) expression was associated with high nuclear grade, suggesting that the presence of BC200 RNA in such tumors may be used as a prognostic indicator of tumor progression. | 15240511 | LncRNADisease Lnc2Cancer |
| EL0276 | CCAT1 | breast cancer | qPCR etc. | BC tissue | up-regulated | expression | Expression levels of lncRNA CCAT1 in BC tissues were significantly higher than those in adjacent normal tissues. High expression of lncRNA CCAT1 was associated with differentiation grade, TNM stage, and lymph node metastases. Kaplan-Meier analysis with the log-rank test indicated that high expression of lncRNA CCAT1 had a decreased overall survival and progression-free survival. Multivariable analysis was further identified high expression of lncRNA CCAT1 as an independent prognosis factor for overall survival and progression-free survival. | 26464701 | Lnc2Cancer |
| EL0278 | CCAT2 | breast cancer | microarray, qPCR, knockdown etc. | breast cancer tissue, cell lines (SUM149, SUM190, MDA-MB-231, MDA-MB-436 etc.) | up-regulated | expression | CCAT2, a novel long non-coding RNA in breast cancer. | 24077681 | LncRNADisease Lnc2Cancer |
| EL0278 | CCAT2 | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue and adjacent normal breast tissue, cell lines (MDA-MB-231, MCF-7) | up-regulated | interaction | We first confirmed the high expression level of CCAT2 in breast cancer tissues and breast cancer cell lines by reverse transcription quantitative polymerase chain reaction (RT-qPCR) assay, and we further analyzed the relationship between CCAT2 expression and clinical prognostic factors. Also, the biological function of CCAT2 was explored and the results showed silencing of CCAT2 could suppress cell growth in vitro and tumor formation in vivo. Finally, our results revealed that the abnormal expression of CCAT2 could influence the Wnt signaling pathway. | 26442763 | Lnc2Cancer |
| EL0289 | CDKN2B-AS1 | breast cancer | N/A | N/A | N/A | locus | A locus associated with breast cancer. | 20453838 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | breast cancer | N/A | N/A | N/A | mutation | More recently, additional GWAS identified ANRIL as a risk locus (rs3217992, A>G;rs1063192, C>T) for several cancers including breast cancer, nasopharyngeal carcinoma, basal cell carcinoma, and glioma. | 20956613 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | breast cancer | N/A | N/A | N/A | locus | A genetic susceptibility locus. | 20956613 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | breast cancer | qPCR etc. | breast cancer tissue | up-regulated | expression | Expression of ANRIL mainly coclustered with p14/ARF both in physiologic (various normal human tissues) and in pathologic conditions (human breast tumors). | 17440112 | LncRNADisease Lnc2Cancer |
| EL0343 | DLEU1 | breast cancer | microarray, qRT-PCR | MCF-7 (ER-positive) and MDA-MB-231 cells (ER- negative) | up-regulated | interaction | MiR-19a might be co-expressed with lncRNA-DLEU1 to co-regulate the expression of ESR1, which influences the occurrence and development of breast cancer cells with different levels of ER expression. | 26416600 | |
| EL0358 | DSCAM-AS1 | breast cancer | cell cultures or fresh tumor biopsies | MCF-8 cells in absence of hormones Erα | N/A | expression | Down-regulation of DSCAM-AS1 recapitulated, in part, the effect of silencing ERα, i.e. growth arrest and induction of EMT markers. | 26621851 | |
| EL0358 | DSCAM-AS1 | breast cancer | qPCR, Northern blot, ISH etc. | cell lines (MCF-7, T47D, ZR-75-1 etc.) | up-regulated | expression | M41 (DSCAM-AS1) mRNA is expressed at a statistically significantly higher level in human breast cancer specimens than in normal human breast and benign lesions. | 12177779 | LncRNADisease Lnc2Cancer |
| EL0363 | EFNA3 | breast cancer | qPCR, RIP etc. | breast cancer tissue | up-regulated | N/A | We demonstrate that sustained expression of both Ephrin-A3 and novel EFNA3 lncRNAs increased the metastatic potential of human breast cancer cells, possibly by increasing the ability of tumor cells to extravasate from the blood vessels into surrounding tissue. In agreement, we found a strong correlation between high EFNA3 expression and shorter metastasis-free survival in breast cancer patients. hypoxia could contribute to metastatic spread of breast cancer via HIF-mediated induction ofEFNA3lncRNAs and subsequent Ephrin-A3 protein accumulation. | 25023702 | Lnc2Cancer |
| EL0366 | EGOT | breast cancer | qPCR etc. | breast cancer tissues, | down-regulated | expression | EGOT expression was lower in breast cancer compared with the adjacent noncancerous tissues, and low levels of EGOT expression were significantly correlated with larger tumor size, more lymph node metastasis, and higher Ki-67 expression. Moreover, patients with low levels of EGOT expression showed significantly worse prognosis for overall survival. Multivariate analysis suggested that low levels of EGOT were a poor independent prognostic predictor for breast cancer patients | 26159853 | Lnc2Cancer |
| EL0476 | EPB41L4A-AS2 | breast cancer | evaluated its relationship with the clinicopathological features | breast cancer tissues | up-regulated | N/A | processes associated with tumor biology | 26980733 | |
| EL0498 | FGF14-AS2 | breast cancer | Reduced expression | breast cancer tissue | down-regulated | expression | FGF14-AS2 involved in the progress of breast cancer and might act as a tumor suppressor gene. | 26820525 | |
| EL0526 | GAS5 | breast cancer | GAS5 HREM sequence alone promotes the apoptosis of breast cancer cells | hormone-sensitive and -insensitive breast cancer cell lines | up-regulated | N/A | induce apoptosis in breast cancer cells | 26862727 | |
| EL0526 | GAS5 | breast cancer | microarray, qRT-PCR | SKBR-3/Tr cells | down-regulated | N/A | GAS5 promoted SKBR-3 cell proliferation | 27034004 | |
| EL0526 | GAS5 | breast cancer | qPCR etc. | cell lines (HEK 293T, LNCaP, W7.2c etc.) | down-regulated | expression | GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. | 18836484 | LncRNADisease Lnc2Cancer |
| EL0526 | GAS5 | breast cancer | qPCR etc. | breast cancer tissues and postoperative blood samples | down-regulated | interaction | Analysis in the 39 paired preoperative and postoperative plasma samples showed that lower GAS5 levels appeared in the patients with a high Ki67 proliferation index before surgery and the patients with a positive lymph node metastasis state after surgery. Plasma lncRNA GAS5 may have the potential to assess the surgical effects and prognosis for BC patients | 26662314 | Lnc2Cancer |
| EL0526 | GAS5 | breast cancer | qPCR, knockdown etc. | cell lines (MCF7, T-47D) | down-regulated | regulation | GAS5?lncRNA?promoted the apoptosis of triple-negative and oestrogen receptor-positive cells but only dual PI3K/mTOR inhibition was able to enhance GAS5 levels in all cell types. Reduced GAS5 expression attenuates apoptosis induction by classical chemotherapeutic agents in breast cancer cells, providing an explanation for the relationship between GAS5 expression and breast cancer patient prognosis.? | 24789445 | LncRNADisease Lnc2Cancer |
| EL0526 | GAS5 | breast cancer | RT-PCR (reverse transcription-polymerase chain reaction) array | breast tumor specimens, xenograft mouse model | N/A | interaction | GAS5 functions as a tumor suppressor. miR-21 is capable of suppressing the lncRNA growth arrest-specific 5 (GAS5). GAS5 can also repress miR-21 expression. | 23933812 | |
| EL0556 | H19 | breast cancer | N/A | N/A | N/A | mutation | Different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. | 21996731 | LncRNADisease |
| EL0556 | H19 | breast cancer | N/A | N/A | N/A | regulation | Control of imprinting. Containing miRNA miR-675. | 22996375 | LncRNADisease |
| EL0556 | H19 | breast cancer | qPCR etc. | cell lines (MCF10A, RPMI 1640, DMEM H21 etc.) | up-regulated | expression | Down-regulation of H19 significantly decreases breast and lung cancer cell clonogenicity and anchorage-independent growth. In addition, c-Myc and H19 expression shows strong association in primary breast and lung carcinomas. | 16707459 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | breast cancer | qPCR etc. | breast cancer tissue | differential expression | mutation | rs2107425 (C>T) near H19 was significantly associated with shorter metastasis-free survival in uni- and multi-variate analysis , with the more aggressive minor allele displaying a recessive trait. | 21748294 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | breast cancer | qPCR, ISH etc. | MDA-MB-231 cell line | up-regulated | expression | Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. | 12419837 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | breast cancer | qPCR, knockdown etc. | breast cancer tissue, cell lines (MCF7, T47D, BT20 etc.) | up-regulated | expression | the transcript is stabilized in breast cancer cells and overexpressed in human breast tumors.91H expression is upregulated in breast cancer. | 18794369 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | breast cancer | qPCR, Northern blot etc. | breast cancer tissue | differential expression | expression | H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary tissue. | 14729626 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MCF-7, MDA-MB-231) | up-regulated | N/A | H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells; H19 lncRNA was much higher in estrogen receptor (ER)-positive MCF-7 breast cancer cells than in ER-negative MDA-MB-231 cells | 25846769 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | breast cancer | RNA CISH etc. | breast cancer tissue | up-regulated | expression | HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. | 26323944 | Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | microarray, qPCR, ISH etc. | breast tumor tissue | up-regulated | N/A | Co-expression of HOTAIR and EZH2 trended with a worse outcome. In matched primary and metastatic cancers, both HOTAIR and EZH2 had increased expression in the metastatic carcinomas. This approach offers a method to make observations on lncRNAs that may influence the cancer epigenome in a tissue-based technique. | 23133536 | Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | HOTAIR showed positive association with 'hang Serum Response'. | 19182780 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | A subsequent study revealed that HOTAIR is overexpressed in approximately one quarter of human breast cancers. | 20930520 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | The lncRNA HOTAIR is a strong predictor of metastasis in breast tumors and its over-expression in various breast carcinoma cell lines promotes invasion. | 21903344 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | Elevated expression of HOTAIR is observed in primary and metastatic breast cancer. | 21925379 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 | 22492512 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | The wellstudied lincRNA, HOTAIR, is highly expressed in breast cancer metastases, and its overexpression in various breast carcinoma cell lines promotes invasion | 22535282 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | Overexpression of the HOTAIR transcript, a cis-lncRNA associated with the HOXD gene cluster, has been associated with hepatocellular carcinoma [32], colorectal cancer [33] and breast cancer [13] by deregulation of HOXD cluster genes | 22817756 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | Gene silencing by interacting with PRC2 and LSD1/CoREST complexes. | 22996375 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | Recent studies have linked their mis-expression to diverse cancers (ANRIL: prostate cancer, XIST: female cancers, HOTAIR: breast cancer, KCNQ1OT3: colorectal cancer). | 23660942 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | Epigenetically silences gene expression via LSD1/CoREST & PRC2; metastasis | 24499465 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | HOTAIR was proposed as a diagnostic marker in breast and colorectal cancer. Its depletion resulted in reduced invasiveness, and its expression level correlated with differentially regulated genes of the PRC2 complex. | 24531795 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | In approximately one-quarter of human breast cancers, HOTAIR is highly induced, while its elevated levels are also predictive of metastasis and disease progression in other cancers, such as colon, colorectal, gastrointestinal, pancreatic and liver cancer. | 24667321 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | expression | For example, HOTAIR is remarkably overexpressed in breast tumors and the expression of HOTAIR in primary breast tumors is a strong prognosis marker of patient outcomes such as metastasis and patient survival | 24721780 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | N/A | N/A | N/A | regulation | Gupta et al found that lncRNA HOTAIR overexpression was a strong predictor of breast tumor metastasis. | 24829860 | LncRNADisease |
| EL0578 | HOTAIR | breast cancer | polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) and created-restriction-site PCR (CRS-RFLP) assays, multifactor dimensionality reduction (MDR) method | N/A | N/A | mutation | Subjects with Trs920778 had a significantly increased risk of breast cancer (OR: 1.41, 95%CI: 1.13, 1.75). We observed a significant interaction between rs920778 and reproductive factors, including age at menopause, number of abortions, and family history. Genetic variant rs920778 in HOTAIR significantly increased the risk of BC, and it may have apparent interaction with reproductive factors in the progression on BC. | 26547792 | |
| EL0578 | HOTAIR | breast cancer | qPCR etc. | breast cancer tissue | differential expression | N/A | A positive correlation was found between DNA methylation and HOTAIR expression. Methylation was associated with unfavorable disease characteristics, whereas no significant associations were found between HOTAIR expression and clinical or pathologic features. In multivariate, but not in univariate, Cox proportional hazard regression models, patients with high HOTAIR expression had lower risks of relapse and mortality than those with low HOTAIR expression. We found that patients with high levels of HOTAIR expression had lower risks of relapse and death than those with low expression. The results suggest that clinicopathological features and therapy treatments could modify the effect of HOTAIR. Large noncoding RNA HOTAIR, transcribed from the antisense strand of HOXC12, interacts with Polycomb Repressive Complex 2 (PRC2) in the regulation of gene activities. | 23124417 | Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | qPCR etc. | cells lines (MCF-7) | up-regulated | interaction | When compared with MCF-7 cells, MCF-7-TNR cells exhibited an increase in the expression of HOTAIR, which correlated with characteristics of a luminal-like to basal-like transition as evidenced by dysregulated gene expression and accelerated growth. MCF-7-TNR cells exhibited reduced suppressive histone H3 lysine27 trimethylation on the HOTAIR promoter. Inhibition of HOTAIR and EZH2 attenuated the luminal-like to basal-like transition in terms of gene expression and growth in MCF-7-TNR cells. HOTAIR was robustly expressed in the native basal-like breast cancer cells and inhibition of HOTAIR reduced the basal-like gene expression and growth. | 25328122 | Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | qPCR, ChIP-chip etc. | cell lines (SUZ12, EZH2, PRC2 etc.) | up-regulated | expression | HOTAIR expression level in primary tumors is a powerful predictor of eventual metastasis and death. | 20393566 | LncRNADisease Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | qPCR, ISH, RIP, ChIP etc. | breast cancer tissue, cell lines (MCF7, T47D) | up-regulated | interaction | In this study, we report that HOTAIR (HOX antisense intergenic RNA) is upregulated in tamoxifen-resistant breast cancer tissues compared to their primary counterparts. Mechanistically, HOTAIR is a direct target of ER-mediated transcriptional repression and is thus restored upon the blockade of ER signaling, either by hormone deprivation or by tamoxifen treatment. Interestingly, this elevated HOTAIR increases ER protein level and thus enhances ER occupancy on the chromatin and potentiates its downstream gene regulation. | 26364613 | Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | real-time polymerase chain reaction (PCR) using TaqMan assay | 123 BC patients and 122 age-matched healthy controls | N/A | mutation | TT genotype of HOTAIR rs12826786 C>T polymorphism was significantly related with multiple clinicopathological characteristics concerned with worse BC progression such as advanced TNM stage (III and IV), larger tumor size (T3 and T4), and distant metastasis (M1), as well as poor histological grade (III) (P < 0.05). | 26577852 | |
| EL0578 | HOTAIR | breast cancer | RNA CISH etc. | breast cancer tissue | up-regulated | expression | HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. | 26323944 | Lnc2Cancer |
| EL0578 | HOTAIR | breast cancer | TaqMan allelic discrimination assay etc. | blood | differential expression | expression | We found that the CC genotype of HOTAIR rs920778 polymorphism significantly increased the risk of BC in both codominant and recessive inheritance genetic models. Our research also indicated an association between the CC genotype of HOTAIR rs920778 polymorphism and clinicopathologic features of tumor, including advanced tumor-node-metastasis (TNM) stage, larger tumor size, distant metastasis, and poor histological grade. CC genotype of HOTAIR rs920778 polymorphism might play important roles in genetic susceptibility to BC development and aggressiveness in a Turkish population. | 25586347 | Lnc2Cancer |
| EL0619 | IRAIN | breast cancer | qPCR etc. | breast cancer tissue | down-regulated | locus | In breast cancer tissues, we found that IRAIN lncRNA was transcribed from an intronic promoter in an antisense diretcion as compared to the IGF1R coding mRNA. Unlike the IGF1R coding RNA, this non-coding RNA was imprinted, with monoallelic expression from the paternal allele. IRAIN was aberrantly imprinted in both tumours and peripheral blood leucocytes, exhibiting a pattern of allele-switch: the allele expressed in normal tissues was inactivated and the normally imprinted allele was expressed. | 25465188 | Lnc2Cancer |
| EL0620 | JADRR | breast cancer | microarray, qPCR, Western blot, in vitro knockdown, RIP etc. | breast cancer tissue, cell lines (293T, NIH3T3, MCF7, 4T1-luciferase etc.) | up-regulated | N/A | Markedly higher levels of lncRNA-JADE were observed in human breast tumours in comparison with normal breast tissues. Knockdown of lncRNA-JADE significantly inhibited breast tumour growth in vivo. | 24097061 | Lnc2Cancer |
| EL0628 | KCNQ1OT1 | breast cancer | RNA CISH etc. | breast cancer tissue | up-regulated | expression | HOTAIR, H19 and KCNQ1OT1 had significantly higher expression levels in IBC than NA, and HOTAIR and H19 were both expressed more strongly in IBC than in DCIS tissues. | 26323944 | Lnc2Cancer |
| EL0647 | LINC00160 | breast cancer | Single-molecule sequencing, chromatin immunoprecipitation and quantitative real-time PCR | luminal A-type human breast cancer cell lines MCF7 and T47D | up-regulated | interaction | Silencing of LINC00160 results in reduced proliferation, demonstrating that lncRNA expression have functional consequences. | 26423156 | |
| EL0670 | LINC00901 | breast cancer | qPCR etc. | breast cancer tissue, cell lines (ZR-75-30, MCF-7, SKBR-3, T47D cells) | down-regulated | expression | It showed that BC040587 expression was down regulated both in BC samples and in BC cell lines compared with corresponding normal control. BC040587 expression was correlated with menopausal status and tumor differentiation. Furthermore, expression of BC040587 was significantly associated with worse prognosis and was shown to be an independent prognostic marker breast cancer. | 25435812 | Lnc2Cancer |
| EL0679 | LINC01016 | breast cancer | Single-molecule sequencing, chromatin immunoprecipitation and quantitative real-time PCR | luminal A-type human breast cancer cell lines MCF7 and T47D | up-regulated | expression | LINC01016 and LINC00160 are direct transcriptional targets of ERα, correlate with Erα expression in clinical samples, and show prognostic significance in relation to breast cancer survival. | 26423156 | |
| EL0718 | linc-ITGB1 | breast cancer | qPCR, Western blot, knockdown, Flow cytometry assay etc. | breast cancer tissue, cell lines (MDA-MB-231, MCF-7, T47D, ZR-75-30, 1590 etc.) | up-regulated | interaction | The expression of linc-ITGB1 was significantly upregulated in both clinical breast cancer tissues and cultured breast cancer cell lines. Linc-ITGB1 depletion caused cell accumulation in the G0/G1 phase. Furthermore, the linc-ITGB1 knockdown decreased the expression of mesenchymal markers N-cadherin and vimentin while increasing the expression of the epithelial marker E-cadherin. Key cell cycle regulators Cdc25C and Cyclin B1 were also decreased by the linc-ITGB1 knockdown. These data suggest that linc-ITGB1 promotes breast cancer progression by inducing cell-cycle arrest and interrupting the epithelial-to-mesenchymal transition (EMT) process. | 26601916 | Lnc2Cancer |
| EL0739 | lincRNA-BC2 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | up-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
| EL0740 | lincRNA-BC4 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | down-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
| EL0741 | lincRNA-BC5 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | up-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
| EL0742 | lincRNA-BC8 | breast cancer | RNA-seq, qPCR etc. | breast cancer tissue | down-regulated | expression | We analyzed lincRNAs whose expression was significantly different between cancer tissues and adjacent tissues. LincRNA-BC2 and lincRNA-BC5 were consistently up-regulated more than 2-fold (mean∮SD) in cancer samples. Whereas, lincRNA-BC4 and lincRNA-BC8 were down-regulated.They might play important roles in the function of oncogenes or tumor suppressors affecting the development and progression of breast cancer. | 25084155 | Lnc2Cancer |
| EL0747 | LINC-ROR | breast cancer | qPCR, vivo knockdown, PIR etc. | breast cancer tissue | up-regulated | N/A | linc-ROR was upregulated in breast tumor and ectopic overexpression of linc-ROR in immortalized human mammary epithelial cells induced an epithelial-to-mesenchymal transition (EMT) program. Moreover,linc-ROR enhanced breast cancer cell migration and invasion. Linc-ROR was associated with miRNPs and functioned as a competing endogenous RNA to mi-205. linc-ROR functions as an important regulator of EMT and can promote breast cancer progression and metastasis through regulation of miRNAs. | 24922071 | Lnc2Cancer |
| EL0797 | lncRNA-AK058803 | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MCF-7) | up-regulated | interaction | The expression levels of lncRNA-AK058003 were increased significantly in the breast cancer tissues and were found to strongly correlate with the severity of the breast cancer clinical stage. | 26136884 | Lnc2Cancer |
| EL0836 | LSINCT1 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0837 | LSINCT10 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0838 | LSINCT11 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0839 | LSINCT12 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0840 | LSINCT2 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0841 | LSINCT3 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0842 | LSINCT4 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0843 | LSINCT5 | breast cancer | N/A | N/A | N/A | expression | Ovarian and breast tumours have also been associated with the expression of the LSINCT5 lncRNA; this transcript acts to target several other transcripts, including the antisense RNA NEAT-1 and the PSPC1 gene, which codes for a splicing regulatory factor | 22817756 | LncRNADisease |
| EL0843 | LSINCT5 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0843 | LSINCT5 | breast cancer | qPCR, Northern blot, etc. | cell lines (HMEC, MCF7, MDA157 etc.) | up-regulated | expression | LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues. | 21532345 | LncRNADisease Lnc2Cancer |
| EL0843 | LSINCT5 | breast cancer | qPCR, Northern blot, knock-down, Microarray | human bronchial epithelial (NHBE) cells, breast cancer cell line, ovarian cancer cell line | up-regulated | expression | knock-down of LSINCT5 expression decreased proliferation in human breast and ovarian cancer cells; Using a genome tiling array to identify noncoding sequences upregulated in normal human bronchial epithelial (NHBE) cells exposed to a DNA-damaging tobacco carcinogen | 26323562 | |
| EL0844 | LSINCT6 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0845 | LSINCT7 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0846 | LSINCT8 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0847 | LSINCT9 | breast cancer | qPCR, Northern blot etc. | cell lines (HMEC, HCC1500, HCC1569 etc.) | up-regulated | N/A | Collectively, our results identified a new class of long stress responsive non-coding transcripts, LSINCTs, which have increased expression in response to DNA damage induced by NNK. LSINCTs interestingly also have increased expression in a number of cancer-derived cell lines, indicating that the expression is increased in both, correlating cellular stress and cancer. | 20214974 | Lnc2Cancer |
| EL0853 | MALAT1 | breast cancer | MALAT1-siRNA | breast cancer tissues and cells | up-regulated | N/A | MALAT1-siRNA inhibited breast cancer cell proliferation and cell cycle progression in vitro and in vivo; and downregulating miR-124 expression | 26918449 | |
| EL0853 | MALAT1 | breast cancer | N/A | breast cancer cells | up-regulated | N/A | MALAT1 induced migration and invasion of breast cancer | 26926567 | |
| EL0853 | MALAT1 | breast cancer | N/A | N/A | N/A | regulation | On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 | 22492512 | LncRNADisease |
| EL0853 | MALAT1 | breast cancer | N/A | N/A | N/A | regulation | Sequesters SR splicing factors to regulate alternative splicing. | 22996375 | LncRNADisease |
| EL0853 | MALAT1 | breast cancer | N/A | N/A | N/A | regulation | invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma | 24499465 | LncRNADisease |
| EL0853 | MALAT1 | breast cancer | qPCR etc. | breast cancer and adjacent non-cancerous specimens, cell lines (MDA-MB-231 and MDA-MB-453) | down-regulated | interaction | We found that MALAT1 was downregulated in breast tumor cell lines and cancer tissue, and showed that knockdown of MALAT1 in breast cancer cell lines induced an epithelial-to-mesenchymal transition (EMT) program via phosphatidylinositide-3 kinase-AKT pathways. Furthermore, lower expression of MALAT1 in breast cancer patients was associated with shorter relapse-free survival | 26191181 | Lnc2Cancer |
| EL0853 | MALAT1 | breast cancer | qPCR, Western blot, Luciferase reporter assays etc. | breast cancer patients tissues | down-regulated | interaction | The effects of up-regulation of miR-1 were similar to that of silencing K-RAS and MALAT1 in breast cancer cells | 26275461 | Lnc2Cancer |
| EL0853 | MALAT1 | breast cancer | qPCR, Western blot, Luciferase reporter assays, RIP etc. | breast cancer specimens and adjacent normal breast tissue | up-regulated | interaction | We reported that MALAT1 was upregulated in triple-negative breast cancer (TNBC) tissues. Knockdown of MALAT1 inhibited proliferation, motility, and increased apoptosis in vitro. In vivo study indicated that knockdown of MALAT1 inhibited tumor growth and metastasis. Patients with high MALAT1 expression had poorer overall survival time than those with low MALAT1 expression. In addition, our findings demonstrate a reciprocal negative control relationship between MALAT1 and miR-1: downregulation of MALAT1 increased expression of microRNA-1 (miR-1), while overexpression of miR-1 decreased MALAT1 expression. Slug was identified as a direct target of miR-1. | 26676637 | Lnc2Cancer |
| EL0853 | MALAT1 | breast cancer | qPCR, Western blot, Northern blot, knockdown etc. | cell lines (MB231, MCF7 etc.) | up-regulated | N/A | Specifically, we looked for the changes of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT-1), which is found extensively and highly expressed in several kinds of tumor cells, including breast carcinoma. It was observed that proliferation, migration and invasion of breast cells were greatly affected by high concentration E2 treatment and were not affected by low concentration E2 treatment in an ERa independent way. We found that the high concentration E2 treatment largely decreased MALAT-1 RNA level. Interestingly, MALAT-1 decreasing by knocking down showed similar effects on proliferation, migration and invasion. | 24525122 | Lnc2Cancer |
| EL0861 | MEG3 | breast cancer | qPCR, ISH etc. | bladder cancer tissue | down-regulated | expression | MEG3 expression is lost. | 14602737 | LncRNADisease Lnc2Cancer |
| EL0880 | MIR31HG | breast cancer | qPCR etc. | cell line (MCF10A) | down-regulated | epigenetics | miR-31 and its host gene lncRNA LOC554202 (MIR31HG) are regulated by promoter hypermethylation in triple-negative breast cancer.Both miR-31 and the host gene LOC554202 are down-regulated in the TNBC cell lines of basal subtype and over-expressed in the luminal counterparts. | 22289355 | LncRNADisease Lnc2Cancer |
| EL0880 | MIR31HG | breast cancer | qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MDA-MB-231, MDA-MB-435S etc.) | up-regulated | regulation | Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. | 24631686 | LncRNADisease Lnc2Cancer |
| EL0950 | MVIH | breast cancer | qPCR, knockdown, Flow cytometry assay etc. | breast cancer tissue, cell lines (MDA-MB-231, MCF-7, T47D, BT-549, UACC-812) | up-regulated | interaction | Our research revealed that the expression levels of MVIH in breast cancer tissues were higher than in adjacent noncancerous tissues, and high MVIH expression was correlated with Ki67 expression. Moreover, breast cancer patients with high MVIH expression levels showed poor overall survival and disease-free survival. Multivariate analysis results indicated that MVIH was an independent prognostic factor in breast cancer. In addition, upregulated MVIH expression levels promoted cell proliferation and cell cycle, and inhibited cell apoptosis, while reduced MVIH expression showed the converse. | 26555546 | Lnc2Cancer |
| EL0961 | NBAT1 | breast cancer | microarray, qPCR, Western blot, RIP, ChIP etc. | cell lines (MCF-7, T47D, ZR75-1, BT-474, MDA-MB-453, BT-549, SK-BR-3 etc.) | down-regulated | interaction | Here, we report that NBAT1 is down-regulated in various types of cancer. Particularly, reduced NBAT1 in breast cancer is associated with tumor metastasis and poor patient prognosis. In vitro, ectopic NBAT1 inhibits migration and invasion of breast cancer cells. Mechanistic study shows that NBAT1 is associated with PRC2 member EZH2 and regulates global gene expression profile. Among them, DKK1 (dickkopf WNT signaling pathway inhibitor 1) is found to be regulated by NBAT1 in a PRC2 dependent manner, and is responsible for NBAT1's effects in inhibiting migration and invasion of breast cancer cells. | 26378045 | Lnc2Cancer |
| EL0973 | NEAT1 | breast cancer | qPCR, ISH etc. | cell lines (MCF-7, MDA-MB-231, MDAMB-468) | up-regulated | expression | Induction of NEAT1 in hypoxia also leads to accelerated cellular proliferation, improved clonogenic survival and reduced apoptosis, all of which are hallmarks of increased tumorigenesis. Furthermore, in patients with breast cancer, high tumor NEAT1 expression correlates with poor survival, all of which are hallmarks of increased tumorigenesis. | 25417700 | Lnc2Cancer |
| EL0977 | NKILA | breast cancer | qPCR, knockdown, RIP etc. | breast cancer tissue | down-regulated | interaction | Importantly, NKILA is essential to prevent over-activation of NF-B pathway in inflammation-stimulated breast epithelial cells. Furthermore, low NKILA expression is associated with breast cancer metastasis and poor patient prognosis. Therefore, lncRNAs can directly interact with functional domains of signaling proteins, serving as a class of NF-B modulators to suppress cancer metastasis. | 25759022 | Lnc2Cancer |
| EL1046 | PANDAR | breast cancer | knockdown of PANDAR | breast cancer tissues and cell lines | up-regulated | N/A | PANDAR in regulating the progression of breast cancer | 26927017 | |
| EL1068 | Pinc | breast cancer | N/A | N/A | N/A | N/A | In a finding of relevance to breast cancer pathogenesis, the mammary gland lncRNA PINC, whose genomic structure is substantially different between primates and rodents has been shown to function in both cell survival and cell cycle progression. | 20951849 | LncRNADisease |
| EL1102 | PVT1 | breast cancer | qPCR etc. | cell lines (A2780, DOV13, PA-1 etc.) | up-regulated | expression | Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. | 17908964 | LncRNADisease Lnc2Cancer |
| EL1102 | PVT1 | breast cancer | qPCR etc. | breast cancer tissue, cell lines (BRF71T1, HCC38, HCC1143 etc.) | up-regulated | N/A | In the 43 breast cancer tissues, PVT1 expression was significantly higher in those with the GG genotype than that in the GA or AA genotype. Compared to normal tissues with any of the genotypes, PVT1 expression was also higher in the tumors with the GG genotype. These findings suggest that the GG genotype of SNP rs13281615 influences breast cancer development likely by modulating PVT1 expression. | 24780616 | Lnc2Cancer |
| EL1107 | RAD51-AS1 | breast cancer | over-expression | Hela cells | up-regulated | locus | Our results identify TPIP as a novel E2F1 co-activator, suggest a similar role for other TPTEs, and indicate that the TODRA lncRNA affects RAD51 dysregulation and RAD51-dependent DSB repair in malignancy . Our results identify TPIP as a novel E2F1 co-activator, suggest a similar role for other TPTEs, and indicate that the TODRA lncRNA affects RAD51 dysregulation and RAD51-dependent DSB repair in malignancy. | 26230935 | |
| EL1144 | KCNK15-AS1 | breast cancer | qPCR etc. | breast cancer tissue | up-regulated | expression | In breast cancer patients, the expression level of lncRNA RP11-445H22.4 is significantly increased. Its expression levels were correlated with estrogen receptor (ER), progesterone receptor (PR), and menopausal status of the breast cancer patients (p < 0.05). | 25929808 | Lnc2Cancer |
| EL1162 | AL121845.1 | breast cancer | microarray, qPCR etc. | breast cancer tissue | up-regulated | interaction | RP4-583P15.10, an up-regulated lncRNA, was found to be located downstream of the natural antisense of the ZBTB46 gene, which may regulated breast cancer through influence immune system. | 25661361 | Lnc2Cancer |
| EL1216 | Smad7 | breast cancer | RNA sequencing, small interfering RNA | mouse mammary gland epithelial cell lines and breast cancer cell lines | N/A | interaction | lncRNA-Smad7 has anti-apoptotic functions, as a target of TGF-β. | 24863656 | |
| EL1236 | SOX2-OT | breast cancer | qPCR, Western blot etc. | cell lines (MCF10A) | up-regulated | N/A | The expression of SOX2 and SOX2OT is concordant in breast cancer, differentially expressed in estrogen receptor positive and negative breast cancer samples and that both are up-regulated in suspension culture conditions that favor growth of stem cell phenotypes. Importantly, ectopic expression of SOX2OT led to an almost 20-fold increase in SOX2 expression, together with a reduced proliferation and increased breast cancer cell anchorage-independent growth. | 25006803 | Lnc2Cancer |
| EL1240 | SPRY4-IT1 | breast cancer | microarray, qPCR, Western blot, knockdown etc. | breast cancer tissue, cell lines (MD-MB-231, MD-MB-435S, MCF-10A, MCF-7 etc.) | up-regulated | interaction | SPRY4-IT1 expression was significantly upregulated in 48 breast cancer tumor tissues comparedwith normal tissues. Additionally, increased SPRY4-IT1 expression was found to be associated with a larger tumor size and an advanced pathological stage in breast cancer patients. SPRY4-IT1 is a novel prognostic biomarker and a potential therapeutic candidate for breast cancer. | 25742952 | Lnc2Cancer |
| EL1241 | SRA1 | breast cancer | N/A | N/A | N/A | expression | Our results demonstrate that full-length SRA-RNAs likely to encode stable proteins are widely expressed in breast cancer cell lines. | 12565891 | LncRNADisease |
| EL1241 | SRA1 | breast cancer | N/A | N/A | N/A | regulation | Co-activator of steroid Receptors & other transcription Factors; associate with metastasis | 24499465 | LncRNADisease |
| EL1241 | SRA1 | breast cancer | qPCR etc. | cell lines (BT-20, MDA-MB-469, MDA-MB-231 etc.) | differential expression | expression | We recently reported a decreased estrogen receptor activity in breast cancer cells overexpressing SRAP, suggesting antagonist roles played by SRA1 RNA and SRAP. | 16848684 | LncRNADisease Lnc2Cancer |
| EL1241 | SRA1 | breast cancer | qPCR, Western blot etc. | breast cancer tissue, cell line (T5) | up-regulated | locus | We have previously found that both fully-spliced SRAP-coding and intron-1-containing non-coding SRA RNAs co-exist in breast cancer cell lines. | 19483093 | LncRNADisease Lnc2Cancer |
| EL1241 | SRA1 | breast cancer | Western blot etc. | cell line (HEK293T ) | differential expression | N/A | Disturbance of the balance between SRAP1-coding and non-coding SRA1 RNAs in breast tumor tissues might be involved in breast tumorigenesis. | 20079837 | LncRNADisease Lnc2Cancer |
| EL1401 | TUNAR | breast cancer | qPCR, Western blot, Luciferase reporter assays, RNA Pull-Down Assay, RPI etc. | breast cancer tissues and adjacent nontumor tissues, cell lines (MCF7, T47D, BT474, and MDA-MB-468) | up-regulated | interaction | We found the human ortholog of TUNA, linc00617, was upregulated in breast cancer samples. Linc00617 promoted motility and invasion of breast cancer cells and induced epithelial-mesenchymal-transition (EMT), which was accompanied by generation of stem cell properties. Moreover, knockdown of linc00617 repressed lung metastasis in vivo. We demonstrated that linc00617 upregulated the expression of stemness factor Sox2 in breast cancer cells, which was shown to promote the oncogenic activity of breast cancer cells by stimulating epithelial-to-mesenchymal transition and enhancing the tumor-initiating capacity | 26207516 | Lnc2Cancer |
| EL1431 | UCA1 | breast cancer | microarray, qPCR, knockdown, ISH etc. | breast cancer tissues and adjacent normal tissues, cell lines(MDA-MB-231) | up-regulated | interaction | UC1 was significantly upregulated, while miR-143 was significantly downregulated in the tumor tissues than in the adjacent normal tissues. There are direct interactions between miR-143 and the miRNA recognition sites of UCA1. UCA1 is present in Ago2-containing RNA-induced silencing complex (RISC), through association with miR-143. Through downregulating miR-143, UCA1 can modulate breast cancer cell growth and apoptosis | 26439035 | Lnc2Cancer |
| EL1431 | UCA1 | breast cancer | microarray, qPCR, Western blot, knockdown, Luciferase reporter assay, RIP etc. | cell lines ( MCF-7, MDA-MB-231, HCT-116 p53-WT, HCT-116 etc.) | up-regulated | regulation | Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). | 24457952 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | breast cancer | qPCR etc. | breast cancer tissue | up-regulated | expression | We found that treatment with macrophage CM induced the expression of numerous lncRNAs, including urothelial cancer associated 1 (UCA1). Knockdown of UCA1 using shRNA inhibited AKT phosphorylation and abolished invasiveness of tumor cells induced by macrophage CM. Consistent with these results; we further showed that UCA1 level was significantly enhanced in human primary breast tumors and correlated with advanced clinical stage, supporting its role in promoting carcinogenesis and progression of breast cancer | 26464647 | Lnc2Cancer |
| EL1459 | XIST | breast cancer | microarray, FISH etc. | breast cancer tissue | differential expression | mutation | The intratumoral and intertumoral variability in XIST RNA domain number in BRCA1 tumors correlates with chromosomal genetic abnormalities, including gains, losses, reduplications, and rearrangements of the X-chromosome. | 17545591 | LncRNADisease Lnc2Cancer |
| EL1517 | ZFAS1 | breast cancer | microarray, Northern blot, ISH etc. | breast cancer tissue | down-regulated | expression | SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer.ZFAS1 is highly expressed in the mammary gland and is down-regulated in breast tumors compared to normal tissue. ZFAS1 is a putative tumor suppressor gene. | 21460236 | LncRNADisease Lnc2Cancer |